Header Logo

Connection

Kalipada Pahan to Gemfibrozil

This is a "connection" page, showing publications Kalipada Pahan has written about Gemfibrozil.
Connection Strength

6.195
  1. Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARa-Dependent Astrocytic GDNF Pathway. J Neurosci. 2021 03 10; 41(10):2287-2300.
    View in: PubMed
    Score: 0.739
  2. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. 2017 06 17; 12(1):113.
    View in: PubMed
    Score: 0.575
  3. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
    View in: PubMed
    Score: 0.567
  4. Activation of peroxisome proliferator-activated receptor a induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J Biol Chem. 2015 Apr 17; 290(16):10309-24.
    View in: PubMed
    Score: 0.491
  5. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
    View in: PubMed
    Score: 0.414
  6. Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-?. J Biol Chem. 2012 Oct 05; 287(41):34134-48.
    View in: PubMed
    Score: 0.411
  7. Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012 Jul 15; 189(2):1002-13.
    View in: PubMed
    Score: 0.407
  8. Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J Biol Chem. 2012 Aug 03; 287(32):27189-203.
    View in: PubMed
    Score: 0.406
  9. Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor ?. Neurochem Res. 2012 Aug; 37(8):1718-29.
    View in: PubMed
    Score: 0.402
  10. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol. 2009; 31(3):339-51.
    View in: PubMed
    Score: 0.320
  11. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol. 2007 Sep 15; 179(6):4142-52.
    View in: PubMed
    Score: 0.293
  12. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol. 2007 Oct; 72(4):934-46.
    View in: PubMed
    Score: 0.289
  13. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor a. Cells. 2023 Dec 08; 12(24).
    View in: PubMed
    Score: 0.225
  14. Activation of PPARa Exhibits Therapeutic Efficacy in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis. J Neurosci. 2023 03 08; 43(10):1814-1829.
    View in: PubMed
    Score: 0.212
  15. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29; 277(48):45984-91.
    View in: PubMed
    Score: 0.207
  16. Activation of Peroxisome Proliferator-Activated Receptor-a Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons. Mol Neurobiol. 2019 Nov; 56(11):7872-7887.
    View in: PubMed
    Score: 0.164
  17. Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin. J Biol Chem. 2007 Nov 02; 282(44):32222-32.
    View in: PubMed
    Score: 0.073
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.